Objective To summarise the effects of herbal medications for the prevention of anxiety, depression, pain, and postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic, obstetrical/gynaecological or cardiovascular surgical procedures. Methods Searches of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and LILACS up until January 2018 were performed to identify randomised controlled trials (RCTs). We included RCTs or quasiRCTs evaluating any herbal medication among adults undergoing laparoscopic, obstetrical/gynaecological or cardiovascular surgeries. The primary outcomes were anxiety, depression, pain and PONV. We used the Grading of Recommendations Assessment, Development and Evaluation approach to rate overall certainty of the evidence for each outcome. results Eleven trials including 693 patients were eligible. Results from three RCTs suggested a statistically significant reduction in vomiting (relative risk/risk ratio (RR) 0.57; 95% CI 0.38 to 0.86) and nausea (RR 0.69; 95% CI 0.50 to 0.96) with the use of Zingiber officinale (ginger) compared with placebo in both laparoscopic and obstetrical/gynaecological surgeries. Results suggested a non-statistically significantly reduction in the need for rescue medication for pain (RR 0.52; 95% CI 0.13 to 2.13) with Rosa damascena (damask rose) and ginger compared with placebo in laparoscopic and obstetrical/ gynaecological surgery.
AbstrACt
Objective To summarise the effects of herbal medications for the prevention of anxiety, depression, pain, and postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic, obstetrical/gynaecological or cardiovascular surgical procedures. Methods Searches of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and LILACS up until January 2018 were performed to identify randomised controlled trials (RCTs). We included RCTs or quasiRCTs evaluating any herbal medication among adults undergoing laparoscopic, obstetrical/gynaecological or cardiovascular surgeries. The primary outcomes were anxiety, depression, pain and PONV. We used the Grading of Recommendations Assessment, Development and Evaluation approach to rate overall certainty of the evidence for each outcome. results Eleven trials including 693 patients were eligible. Results from three RCTs suggested a statistically significant reduction in vomiting (relative risk/risk ratio (RR) 0.57; 95% CI 0.38 to 0.86) and nausea (RR 0.69; 95% CI 0.50 to 0.96) with the use of Zingiber officinale (ginger) compared with placebo in both laparoscopic and obstetrical/gynaecological surgeries. Results suggested a non-statistically significantly reduction in the need for rescue medication for pain (RR 0.52; 95% CI 0.13 to 2.13) with Rosa damascena (damask rose) and ginger compared with placebo in laparoscopic and obstetrical/ gynaecological surgery. None of the included studies reported on adverse events (AEs). Conclusions There is very low-certainty evidence regarding the efficacy of both Zingiber officinale and Rosa damascena in reducing vomiting (200 fewer cases per 1000; 288 fewer to 205 fewer), nausea (207 fewer cases per 1000; 333 fewer to 27 fewer) and the need for rescue medication for pain (666 fewer cases per 1000; 580 fewer to 752 more) in patients undergoing either laparoscopic or obstetrical/gynaecological surgeries. Among our eligible studies, there was no reported evidence on AEs. PrOsPErO registration number CRD42016042838 IntrOduCtIOn Postoperative nausea and vomiting (PONV) and pain account for over half of reported symptoms by surgical patients. 1 Defined as nausea and/or vomiting occurring within 24 hours after surgery, reported PONV prevalence among surgical patients ranged from 25% to 30% in a number of studies, and have been reported to be as high as 80%. 2 3 PONV decrease quality of life and is rarely the result of a single factor (metabolic, vestibular and psychogenic disturbances, gastrointestinal and intracranial disorders), and therefore its management may not be successful. 4 5 Depression and anxiety are also very frequent worldwide in terms of perioperative symptoms for patients undergoing surgery, and have been associated with prolonged durations for recovery. 6 7 Reported prevalence of anxiety have been reported to be as high as 80% in the perioperative period, 8 9 strengths and limitations of this study ► We included randomised controlled trials (RCTs) or quasi-RCTs evaluating any herbal medication among adults undergoing laparoscopic, obstetrical/ gynaecological or cardiovascular surgeries. ► No restrictions were placed on language, year of publication or publication status. ► The evaluation of eligibility, risk of bias and data abstraction were made independently and in duplicate. ► The Grading of Recommendations Assessment, Development and Evaluation approach was used in rating the certainty of evidence; and we present both absolute and relative effects of the interventions for patient-important outcomes.
Open access and has been reported to be higher among those with chronic medical conditions relative to the general population. 10 Further, depression and anxiety disorders have been associated with increased rates of readmission, 11 morbidity 12 and mortality 13 in surgical patients. Evidence from the USA suggests 70% to 80% of the 23 million people who undergo surgical procedures annually experience moderate to severe pain. 14 Another study reported a postoperative pain prevalence of 52.5% in the first 24 hours and 41.1% on the second postoperative day for hospitalised surgical patients, with the most common type of pain reported by patients being musculoskeletal (54%). 15 Generally, pain decreases over time but may persist for days or even months postoperatively. 16 Postoperative pain may complicate recovery and delay discharge of patients as well. 17 Use of herbal medications by surgical patients is quite common worldwide. For instance, a study of hospitalised patients in a public medical centre in Israel found that 44% reported using herbal medications in the last year; 89 different remedies were reportedly used. 18 In comparison, the estimated prevalence of herbal medications use for patients undergoing surgery in the USA has been reported to range from 32% to 51%. 19 While herbal medications have been associated with positive effects on postoperative pain, anxiety and PONV, [20] [21] [22] they have been associated with side effects of their own. Additionally, there may also be concerns regarding interactions with conventional medications and associated perioperative adverse events such as bleeding, cardiovascular instability, coagulopathy, excessive somnolence, photosensitivity and endocrine and electrolyte disturbances. [23] [24] [25] [26] [27] [28] [29] Despite growing knowledge about herbal medications and drug interactions, most of these concerns have arisen based on theoretical data rather than clinical evidence from surgical patients. 30 The American Society of Anesthesiology (ASA) recommends discontinuing herbal medication consumption 2 weeks prior to surgery. 31 Nevertheless, a recent study in Columbia showed that only around 23% of preoperative surgical patients discontinue their herbal medication regimens prior to surgery. 32 No recent systematic reviews evaluating herbal medications in patients undergoing surgical procedures for perioperative and postoperative symptom control were identified. As such, we undertook a systematic review summarising the efficacy and safety of herbal medications for the prevention of anxiety, depression, pain and PONV in patients undergoing laparoscopic, obstetrical/gynaecological and cardiovascular surgical procedures.
MEthOds
The Cochrane Handbook for Intervention Reviews 33 guided our choice of methods. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement 34 and also the PRISMA checklist 34 were used when writing this report.
This systematic review was registered in PROSPERO (International Prospective Register of Systematic Reviews), and the protocol was also published elsewhere. searching other resources In addition to an electronic database search, we made a manual search in the reference lists of every study deemed eligible in order to identify additional trials that were later included; all potentially eligible studies were screened in duplicate. Furthermore, the coauthors leading eligible trials were contacted for additional data and information that could be potentially included.
selection of studies Pairs of reviewers independently screened all titles and abstracts identified by the search. Full-text articles for potentially eligible studies were obtained and screened independently by reviewer pairs using the same eligibility criteria as with title and abstract screening. Consensus for both stages of screening, were established by discussion and adjudication by a third reviewer as necessary.
data extraction and risk of bias assessment Once a final set of eligible studies were identified, reviewer pairs independently extracted data for the following variables from each study using a pre-standardised data extraction form with: characteristics of the study design; participants; interventions; outcomes event rates (for afore mentioned primary and secondary outcomes) and duration of follow-up. Reviewers independently assessed risk of bias by using a modified version of the Cochrane Collaboration's tool. The tool includes nine domains: adequacy of sequence generation, allocation sequence concealment, blinding of participants and caregivers, blinding of data collectors, blinding for outcome assessment, blinding of data analysts, incomplete outcome data, selective outcome reporting and the presence of other potential sources of bias not accounted for in the previously cited domains. 36 37 For incomplete outcome data, we considered a loss to follow-up of less than 10% and a difference of less than 5% in missing data in intervention and control groups as low risk of bias. Reviewers discussed with a third party adjudication to resolve disagreements.
Confidence in pooled estimates of effect
The reviewers used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate quality of evidence for each outcome. Quality ratings were assigned as high, moderate, low, or very low. 37 Detailed GRADE guidance was used to assess overall risk of bias, 38 imprecision, 39 inconsistency, 40 indirectness 41 and publication bias. 42 Consensus was established by discussion and adjudication by a third reviewer as necessary, and final results were summarised in an evidence profile (table 5) .
data synthesis and statistical analysis Pooled risk ratios (RRs) were calculated for dichotomous outcomes and standardised mean differences for continuous variables with the associated 95% CIs using random-effects models with the Mantel-Haenszel statistical method. Absolute effects and 95% CI were calculated by multiplying pooled RRs and 95% CI by baseline risk estimates derived from the largest included RCTs for each respective herbal remedy in our meta-analysis.
Variability was addressed in results across studies by using I 2 statistic and the p value obtained from the Cochran Q (χ 2 ) test. Our primary analyses were based on eligible patients who had reported outcomes at the last time-point for each study (complete case analysis).
We planned to perform separate analyses to assess publication bias through visual inspection of funnel plots for outcomes addressed in 10 or more studies; however, the information from the included studies was insufficient for performance of any of these analyses.
We avoided double-counting of participants where there were multiple publications in the same population. If there was more than one published report of the same group of patients, the articles were analysed to verify Open access whether or not they reported different outcomes. If they presented the same outcomes we extracted the data from the most recent or most complete article. We used Review Manager (RevMan) (V.5.3; Nordic Cochrane Centre, Cochrane) for all analyses. 43 
Patient and public involvement
No patients or members of public were involved in this study.
rEsults
Our initial searches identified 8382 citations. All were from electronic searches. After we removed duplicates from different databases, we retained 4810 potentially relevant articles for further assessment. After reading titles and abstracts, we excluded 4719 of these articles because they were duplicates, non-clinical studies or had study objectives that were different from this review. Ninety-one articles published in Chinese or English were retrieved for further assessment. After screening the full text, we included 76 randomised clinical trials of the 91 trials, and we found another trial through reading reference lists of other references. Therefore, we included 77 randomised clinical trials. We excluded 15 studies after reviewing the full papers, and listed the reasons for exclusion in the characteristics of excluded studies table. We prepared a PRISMA flow diagram to describe the publications found through our searches (figure 2).
search selection
The initial searches identified 7210 titles from the electronic searches. After the duplicates, titles were removed, 6775 potentially relevant articles were retained for further assessment (figure 1). Subsequent to reading titles and abstracts, 6715 of these articles were excluded because they were off-topic, in vitro or animal studies. Sixty articles were retrieved for further assessment. After screening the full texts, 11 (one with two publications) RCTs or quasi-RCT [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] were included in the qualitative synthesis (figure 1).
Five 45 46 48 52 53 55 of the included trials were published in Chinese. Authors of all included studies were contacted for further clarification regarding items of their methodology for our risk of bias analysis, but none of them supplied us with the requested information. Table 2 describes study characteristics related to the design of the study, the setting, number of participants, mean age, gender, inclusion and exclusion criteria, and follow-up. Ten [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] were RCTs, and one 44 were quasi-RCT. Nine 44-50 52-54 trials employed a parallel two-arm design. Five trials 45 46 48 52 53 55 were conducted in China, three 47 51 54 in Iran, two 44 49 in Thailand, and one 50 in France. The trials sample size ranged from 20 50 to 120 49 patients. Participants were adults with mean ages ranging from 22.30 47 to 63.00 years. 50 The majority of the eligible studies among the cardiovascular surgical procedures included patients with rheumatic heart disease of ASA grade II-III. 45 46 52 55 For the included studies among the obstetrical/gynaecological procedures the most common inclusion criteria were pregnant patients 47 54 and ASA grade I or II 49 while for the laparoscopic procedures, patients typically enrolled included non-cancer gynaecological conditions. 44 Studies followed participants from 2 hours 51 to 15 days 50 (table 2) . Table 3 describes study characteristics related to type of surgery, intervention and control groups, and measured outcomes. In relation to the type of surgery, seven 45 46 48 50-53 55 included studies evaluated patients undergoing cardiovascular surgical (mostly undergoing heart valve replacement), three 47 49 54 obstetrical/gynaecological and, one 44 laparoscopic procedure. Among cardiovascular surgery 45 46 48 50-53 55 studies, Ginkgo biloba was used in two 45 46 50 studies and Astragalus in two, 52 55 and herbal medications were mostly used in the form of mixture 48 50 52 53 55 or standardised extract. 45 46 Five of these studies reported the use of herbal medication via intravenous, 45 49 54 and in other Open access 
study characteristics
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Rosa damascena (damask rose), 47 in the form of powder 47 49 and administered via oral. 47 49 54 Placebo was used as the control group. 47 49 54 None of the included studies assessed conventional treatment or types of complementary and alternative therapy. The measured outcomes evaluated were pain, 47 nausea 49 54 and vomiting 49 54 (table 3) . The only included study 44 that evaluated laparoscopic procedure used Zingiber officinale in the form of powder by oral route (capsules), while placebo was used as the control group. The measured outcomes were nausea and vomiting (table 3) . Figure 2 and figure 3 ). Certainty in evidence was rated down to very low because of risk of bias (due to lack of reporting of allocation concealment, 44 lack of blinding of caregivers, 44 data collectors, 44 data analyst, 44 49 54 outcome assessment 44 54 ), indirectness and imprecision (fewer than 300 to 400 events) (table 5).
risk of bias assessment
Nausea
Results from two RCT 49 54 with a total of 212 participants suggested a statistically significantly reduction in nausea with the use of Zingiber officinale compared with the control group (ie, placebo and tap water) in obstetrical/ gynaecological surgery (RR 0.69, 95% CI 0.50 to 0.96; p=0.03; I 2 =0%, p=0.39) (figure 4). Certainty in evidence was rated down to very low because of risk of bias (due to lack of blinding of data analyst 49 54 and outcome assessment, 54 selective outcome reporting 49 ), imprecision (fewer than 300 to 400 events), and indirectness in both studies (table 5) .
Pain
Results from one RCT 47 with a total of 92 participants suggested a statistically significantly reduction in pain with the use of Rosa damascena powder capsules compared with placebo in obstetrical/gynaecological surgery (RR 0.14, 95% CI 0.07 to 0.30; p=0.00001) The authors 47 reported that Rosa damascena group presented only 17% of postoperative pain and control group presented 97%. Certainty in evidence was rated as very low because of risk of bias (due to random generation, allocation concealment, lack C, control group; HM1, herbal medicine group 1; HM2, herbal medicine group 2; HM3, herbal medicine group 3; I, intervention; IVC, Intervention vitamin C; no, number.
Table 3 Continued
Open access of blinding of data analyst, selective outcome reporting), imprecision (fewer than 300 to 400 events), and indirectness (table 5) .
Need for rescue medication for pain
Results from three RCTs 44 47 49 with a total of 272 participants suggest a non statistically significantly reduction in the need for rescue medication for pain between Rosa damascena and Zingiber officinale powder capsules compared with placebo in laparoscopic and obstetrical/gynaecological surgery (RR 0.52, 95% CI 0.13 to 2.13; p=0.36; I 2 =92%, p=0.00001) ( figure 5, panel A) . A plausible worse case sensitivity analysis excluding Gharabaghi et al 47 study yielded results that were consistent with the primary analysis and fail to show a difference in the effects of herbal medications compared with placebo (RR 0.87, 95% CI 0.66 to 1.14; p=0.31; I 2 =0%, p=0.53; I 2 =0%) ( figure 5, panel B) . Certainty in evidence was rated down to very low because of risk of bias (related to random generation, 47 allocation concealment, 44 47 lack of blinding of caregivers, 44 data collectors, 44 statistician 44 47 49 ) and outcomes assessment, 44 selective outcome reporting, 47 49 indirectness, imprecision (fewer than 300 to 400 events), and inconsistency (table 5) .
Anxiety and depression
None of the included studies reported on these outcomes.
secondary outcomes Adverse events
None of the included studies reported on this outcome.
Number of patients reporting adverse events
Quality of life
Satisfaction with herbal medications
Need for rescue medication
None of the included studies reported on this outcome. Open access All answers as: definitely yes (low risk of bias), probably yes, probably no, definitely no (high risk of bias).
Open access
Duration of symptoms None of the included studies reported on this outcome.
Qualitative analysis of non patient-important outcomes Seven trials 45 46 48 50-53 55 from the qualitative analysis assessed different types of biochemical analyses during cardiovascular surgical procedures. Two 45 46 50 of them analysing Ginkgo biloba found an improvement in the cerebral oxygen supply and inhibit production of free radicals 45 and that the extract displays an erythrocyte protecting effect alleviating the lipid peroxidation in their membrane 46 ; and that Ginkgo biloba (EGb 761) may be useful as an adjuvant therapy in limiting oxidative stress in cardiovascular surgery. 50 Furthermore, two trials analysing Astragalus found that it may decrease the inflammation cytokine promoting factors and increase the level of anti-inflammatory cytokine, 52 and that Astragalus plus ligustrazine (bioactive ingredient extracted from the Chuanxiong herb) can effectively protect against myocardial ischemia reperfusion injury. 55 Among the remaining studies, Huang et al 48 evaluated Radix Salviae Miltiorrhizae and found effects towards the prevention of lung leucocyte aggregation and a reduction in the production of lung free radical products while the study of Safaei et al 51 tested the effect of Vitis vinifera and found an antioxidative effect during coronary artery bypass grafting surgery. Lastly, Xie et al 53 study explored the effect of Puerarin injection (bioactive ingredient isolated from the root of the Pueraria lobata) and found that it can protect the myocardium soon after the ischaemia reperfusion.
dIsCussIOn
Main findings
From laparoscopic and obstetrical/gynaecological surgeries, based on 212 surgical patients evidence suggests a statistically significant reduction in both vomiting and nausea favouring Zingiber officinale and in the need for rescue medication for pain favouring both Rosa damascena and Zingiber officinale. We also found favourable results for Rosa damascena and Zingiber officinale for pain 47 associated with obstetrical/gynaecological surgery, with the overall certainty in evidence rated as very low (table 5) .
Regarding the herbal medication Zingiber officinale, it is widely used around the world for nausea, vomiting and motion sickness. 44 49 54 In a systematic review that included six RCTs, 56 Zingiber officinale was evaluated for nausea and vomiting. Three of these RCTs evaluated PONV, with two of them suggesting that Zingiber officinale was superior to placebo and equally effective as metoclopramide (an antiemetic drug). The pooled absolute risk reduction for the incidence of postoperative nausea, however, indicated a non-significant difference between Zingiber officinale (dose: 1 g/day) and placebo when taken prior to surgery (absolute risk reduction 0.05 (95% CI 0.08 to 0.18). These studies collectively favoured Zingiber officinale over placebo.
In another systematic review 57 that evaluated Zingiber officinale in the treatment of pregnancy-associated nausea and vomiting, 12 RCTs involving 1278 pregnant women were included. Zingiber officinale was compared with placebo and significantly improved the symptoms of nausea (mean difference (MD) 1.20, 95% CI 0.56 to 1.84, p=0.0002, I 2 =0%). Zingiber officinale did not significantly reduce the number of vomiting episodes, when compared with placebo, although there was a trend towards improvement (MD 0.72, 95% CI 0.03 to 1.46, p=0.06, I 2 =71%). Zingiber officinale is thought to act peripherally, within the gastrointestinal tract, increasing the gastric tone and motility due to anticholinenergic and antiserotonergic actions 58 and it has also been reported that Zingiber increase gastric emptying. 59 These activities may explain the ability of Zingiber officinale to relieve symptoms of gastrointestinal disorders, such as abdominal pain, and nausea, which is often associated with decreased gastric motility. 59 There is little available in the literature on potential adverse effects associated with Zingiber officinale, with some data suggesting that its components may be mutagenic. 60 61 Based on our findings as well as the results of other systematic reviews, 56 57 Zingiber officinale has potential as a possible alternative anti-emetic and anti-nausea drug for surgical patients, although this must be verified with further research using standardised forms of the herb with the constituents thought to be most active, for instance, 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol. 62 In relation to pain, Rosa damascena has been tested in pre-clinical studies 63 64 for anti-inflammatory and analgesic properties, and in clinical studies for analgesic and antinociceptive effects. 65 66 Similar to our findings, a systematic review 67 showed promising evidences for its effectiveness and safety in pain relief. Although these Figure 3 Meta-analysis comparing herbal versus placebo on vomiting for laparoscopic or obstetrical-gynaecological. 44 49 54 and outcomes assessment. 44 54 †Serious limitations related to surgery where the results are not applicable for cardiac surgery. ‡Serious imprecision related to outcome (fewer than 300 to 400 events). §Serious limitations related to lack of blinding of data analyst, 49 54 and outcomes assessment 54 and selective outcome reporting. 49 ¶Serious limitations related to random generation, allocation concealment, lack of blinding of data analyst and selective outcome reporting.
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47
**Serious limitations related random generation, 47 allocation concealment, 44 47 lack of blinding of caregivers, 44 data collectors, 44 data analyst 44 47 49 and outcomes assessment, 44 selective outcome reporting. 47 49 † †Serious limitation related to inconsistency (I 2 =92%).
Open access positive findings, [63] [64] [65] [66] [67] these results must be cautiously interpreted. Rosa damascena presents as a promising indication for the effectiveness in pain relief but more studies are needed. Rosa damascena 68 petals infusion has been tested for toxicity and it was well tolerated, showing minimal nephrotoxic or hepatotoxic effects, unless it is used at extreme doses.
Another focus of this manuscript was to assess potential adverse events with the use of herbal medication, but none of the eligible trials reported this information. Considering all the data evaluated in the present study, we reiterate the importance of patients continuing to follow the guidance provided by ASA, 31 which was previously described in the introduction, which is to discontinue herbal medications 2 weeks prior to an elective surgery.
There is a general perception that herbal medications or drugs are safe and devoid of adverse effects, but this can be misleading. Caution is needed when dealing with herbal medication, because they have been shown to be capable of producing a wide range of undesirable or adverse reactions such as clinically significant drug interactions which may impact the efficacy of standard and proven medications. 69 70 . strengths and limitations Strengths of this review include a broad search; evaluation of eligibility, risk of bias, and data abstraction independently and in duplicate; use of the GRADE approach in rating the quality of evidence; and focus on both absolute and relative effects of the intervention on patient important outcomes.
Potential limitations are related to the data available for this topic on the current literature. Trials often had outcomes reported incompletely, inadequate reporting of random sequence generation, and often neglected to blind participants and study personnel due to the nature of the intervention. A second limitation of this review is the fact that we were able to include only eleven trials including 693 patients (364 patients in the meta-analysis), thus limiting the statistical power for some of our pre-defined outcomes and as a result we rated down for imprecision. A third limitation was that the trials that used Zingiber officinale for vomiting and nausea, also presented some heterogeneity in their plant preparation, although all of them were administered orally, Apariman et al Differences between our PROSPERO protocol and our final review minimal, but included the review only on testing the impact of herbal medicine before surgery to evaluate prophylactic effects on anxiety, depression, pain, nausea and vomiting post intervention. We choose to include only preoperative interventions to minimise Open access the potential interaction with the postoperative medications (eg, anti-emetics, painkillers) on the predefined outcomes.
Implications for clinical practice and for research
There is very low-certainty evidence showing that Zingiber officinale is more effective than placebo for the reduction of vomiting (laparoscopic and obstetrical/gynaecological surgery) and nausea (obstetrical/gynaecological surgery) in patients. Similarly, there is very low-certainty evidence showing that Rosa damascena is more effective than placebo for the reduction of pain in patients undergoing obstetrical/gynaecological surgery. Finally, there is also very low-certainty evidence showing that Rosa damascena and Zingiber officinale are more effective than placebo for reducing the need for rescue medication for pain in laparoscopic and obstetrical/gynaecological surgeries. editing.
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